Upon SynNotch engagement, CAR is produced atthe proximity of tumor regions, where the clinically validated antigencan be potentially introduced to express in a subset of cancer cellsas “training centers” through genetic modification.Notably, CD19 is expressed on the surface of B cells; therefore, leakyCAR expression due to B cell exposure is a concern. The gene discussed is CD19; the disease is cancer.